This site is intended for Healthcare professionals only.

Johnson and Johnson’s quarterly profit rises 3.3 percent


Johnson and Johnson’s quarterly profit rises 3.3 percent

Johnson and Johnson reported a 3.3 percent rise in quarterly profit, as higher sales of cancer drugs Zytiga and Darzalex helped offset pressure on its blockbuster rheumatoid arthritis treatment Remicade.

The healthcare conglomerate’s net earnings rose to $3.95 billion, or $1.45 per share, in the second quarter, from $3.83 billion, or $1.40 per share, a year earlier.

Sales rose to $20.83 billion from $18.84 billion.

(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)



Source: REUTERS
0 comment(s) on Johnson and Johnson’s quarterly profit rises 3.3 percent

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted